The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Solazyme met expectations on revenues and exceeded expectations on earnings per share.
Compared to the prior-year quarter, revenue dropped and GAAP loss per share increased.
Margins dropped across the board.
Solazyme reported revenue of $8.6 million. The 10 analysts polled by S&P Capital IQ looked for a top line of $8.6 million on the same basis. GAAP reported sales were 4.0% lower than the prior-year quarter's $8.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.32. The four earnings estimates compiled by S&P Capital IQ anticipated -$0.34 per share. GAAP EPS were -$0.37 for Q3 versus -$0.24 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 84.5%, 930 basis points worse than the prior-year quarter. Operating margin was -269.5%, 11,270 basis points worse than the prior-year quarter. Net margin was -262.2%, 10,460 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $11.1 million. On the bottom line, the average EPS estimate is -$0.33.
Next year's average estimate for revenue is $47.2 million. The average EPS estimate is -$1.16.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 335 members out of 356 rating the stock outperform, and 21 members rating it underperform. Among 68 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 58 give Solazyme a green thumbs-up, and 10 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Solazyme is outperform, with an average price target of $18.50.
Are you missing a major story in the energy space? Read about "One Stock to Own Before Nat Gas Act 2011 Becomes Law." Click here for instant access to this free report.
- Add Solazyme to My Watchlist.